By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Qiagen has increased the offering price for its proposed acquisition of Australian biotech firm Cellestis.

The offering price has been increased from A$3.55 (US$3.79) per share to A$3.80 per share, under the terms of an amended proposal. The transaction value for the deal has increased to US$374 million from US$355 million, Qiagen said Monday.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: variant linked to canine cleft lip, new compression tool, and more.

GNC will start using DNA testing to authentic the presence of plants included in its labels, following an agreement with the New York Attorney General.

Fareed Zakaria writes that instead of focusing solely on STEM-related courses, students would do well to pursue the liberal arts if they want to be technology innovators.

A Harvard Business Review study found four major patterns of gender biases and added that black and Latina scientists further had to navigate racial stereotypes.